Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Change from original agreement

Terms/Details (Date)


AstraZeneca plc (UK)

Extended research collaboraration in which Astex will continue to apply its high-throughput X-ray crystallography technology to obtain crystal structures of human cytochrome P450s alone and in complex with AstraZeneca's compounds

Financial terms were not disclosed (7/7)

Compugen Ltd. (Israel; CGEN)

Novartis Pharma AG (Switzerland)

Extended license of Compugen's LEADS platform for another year

Compugen will design a genome-wide collection of DNA probes for Novartis (6/16)

Cubist Pharmaceuticals Inc. (CBST)

Eli Lilly & Co.

Modified agreement in which Cubist purchased a reduction in the royalties payable to Lilly on netsales of Cidecin

Cubist acquired rights from Lilly in 1997; it will issue to Lilly $8M in stock and the global royalty obligation will be reduced by 1% (7/2)

Cypress Bioscience Inc. (CYPB)

Pierre Fabre Medicament SA (France)

Modified milnacipran agreement

Cypress exercised its option for an exclusive license to develop and sell any milnacipran product for all indications in the U.S. and Canada; Pierre Fabre will continue to have the right to manufacture raw material needed for milnacipran products, and will receive 1M shares of Cypress stock and a warrant to purchase another 300,000 shares (6/9)

Genedata AG* (Switzerland)

Novartis Pharma AG (Switzerland)

Extended multiyear collaboration to provide a license to Genedata's PathoLead Edition of its Phylosopher platform as well as consulting services to the Novartis Institutes for BioMedical Research Inc.

Financial terms were not disclosed (6/18)

Genentech Inc. (NYSE:DNA)

F. Hoffmann-La Roche Ltd. (Switzerland)

Exercised option in which Roche gains non-U.S. rights to Genentech's Avastin

Genentech retains rights in the U.S. (7/8)

GPC Biotech AG (Germany; FSE:GPC)

Altana Pharma AG (Germany)

Expanded collaboration and license agreement to include GPC's LeadCode technology to evaluate compounds in the public domain as well as Altana Pharma compounds

GPC will receive committed funding for the license, transfer and implementation of LeadCode for use at the Altana Research Institute, which will be established through the collaboration; GPC could receive more than $15M in milestone payments, and Ariad will receive license payments of $1M over the next 20 months, as well as additional license fees (6/13)

Isis Pharmaceuticals Inc. (ISIS)

Eli Lilly and Co.

Modified manufacturing agreement for Affinitak

Lilly agreed to waive a $21M manufacturing loan repayment from Isis; Isis agreed to let Lilly out of its Affinitak supply obligations; the changes were made following Affinitak's disappointing Phase III non-small-cell lung cancer trial (6/5)


Merck & Co. Inc.

Extended multiyear research collaboration to discover and develop anti-infective compounds

Scynexis will use its Medchem-Factory and Heos technologies to help accelerate the identification of drugs active against Merck's screening targets; Merck would receive exclusive worldwide rights to any products developed through the collaboration; Scynexis would receive milestone payments on developed products and royalties on sales (7/16)


Procter & Gamble Pharmaceuticals

Renewed agreement to provide P&G access to Sequitur's functional genomics technology

The agreement also was expanded to include additional therapeutic areas (5/22)

Speedel Group* (Switzerland)

F. Hoffmann-La Roche Ltd. (Switzerland)

Exercised option for Speedel to license exclusive worldwide rights for the full development and commercialization to SPP301 from Roche

Speedel paid an undisclosed milestone for its part of the agreement (5/22)


CeNeS Pharmaceuticals plc (UK; LSE:CEN)

Elan Corp. plc (Ireland)

Terminated joint venture that was created in 2001 to develop M6G to treat pain

CeNeS will fund the clinical development of M6G by itself; no more funding will be available to CeNeS under the convertible loan stock arrangements entered in June 2001 (6/18)

Cytogen Corp. (CYTO)

Berlex Laboratories (U.S. affiliate of Schering AG; Germany)

Terminated agreement for rights to the cancer pain product Quadramet

Cytogen regained rights to Quadramet and agreed to make an up-front payment and issue royalties on future sales; it regained North and South American marketing rights (6/16)

Generex Biotechnology Corp. (Canada; GNBT)

Eli Lilly and Co.

Terminated development and license agreement for a buccal delivery of insulin

Both parties are working on terms for Lilly to continue to supply a specified amount of insulin for Generex's further development work; Generex regains all rights to the buccal spray drug delivery technology (5/27)

Gilead Sciences Inc. (GILD)

Bukwang Pharm. Ind. Co. Ltd. (South Korea)

Terminated licensing agreement related to clevudine, which is in development for chronic hepatitis B

The collaboration began in February 1998 between Bukwang and Triangle Pharmaceuticals Inc., which was acquired by Gilead last year (6/24)

PPL Therapeutics plc (UK; LSE:PTH)

Bayer Healthcare

Terminated agreement for the development of alpha-1- antitrypsin

Bayer decided to stop the project and re- group due to a delay between Phase II and Phase III trials and the absence of a manufacturing site (6/19)


Elan Corp. plc (Ireland)

Terminated agreement in which RxKinetix acquired exclusive development rights to RK-0202, an oral rinse for oral mucositis that is in Phase II development

RxKinetix will pay a royalty to the joint venture on certain revenues (6/3)

Group plc

F. Hoffmann-La Roche Ltd. (Switzerland)

Terminated option on Vernalis' adenosine A2A antagonist research program in depression

Vernalis now has control over the pro- grams, which target a range of indications including Parkinson's disease and depression (6/5)


Baxter Healthcare Corp.

Terminated agreement for Neuprex

XOMA will receive a one-time, $10M payment after terminating the license and supply agreements with Baxter (7/8)


# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange.